Dosiomics in lung cancer

Conflict of interest

The author declares that she has no conflict of interest and has no competing interests.

References

[1] Dudas D, Dilling TJ, Naqa IE. A deep learning-informed interpretation of why and when dose metrics outside the PTV can affect the risk of distant metastasis in SBRT NSCLC patients. Radiat Oncol. 2024; 19(1):127. doi: 10.1186/s13014-024-02519-1

[2] Ma Z, Liang B, Wei R, et al. Enhanced prediction of postoperative radiotherapy-induced esophagitis in non-small cell lung cancer: Dosiomic model development in a real-world cohort and validation in the PORT-C randomized controlled trial. Thorac Cancer. 2023; 14(28):2839-2845. doi: 10.1111/1759-7714.15068

[3] Zhou L, Wen Y, Zhang G, Wang L, Wu S, Zhang S. machine learning-based multiomics prediction model for radiation pneumonitis. J Oncol. 2023;2023:5328927. doi: 10.1155/2023/5328927

[4] Adachi T, Nakamura M, Shintani T, et al. Multi-institutional dose-segmented dosiomic analysis for predicting radiation pneumonitis after lung stereotactic body radiation therapy. Med Phys. 2021; 48(4):1781-1791. doi: 10.1002/mp.14769

[5] Monti S, Xu T, Liao Z, Mohan R, Cella L, Palma G. On the interplay between dosiomics and genomics in radiation-induced lymphopenia of lung cancer patients. Radiother Oncol. 2022; 167:219-225. doi: 10.1016/j.radonc.2021.12.038

[6] Puttanawarut C, Sirirutbunkajorn N, Tawong N, et al. Radiomic and dosiomic features for the prediction of radiation pneumonitis across esophageal cancer and lung cancer. Front Oncol. 2022;12:768152. doi: 10.3389/fonc.2022.768152

[7] Zhang Z, Wang Z, Yan M, et al. Radiomics and dosiomics signature from whole lung predicts radiation pneumonitis: A model development study with prospective external validation and decision-curve analysis. Int J Radiat Oncol Biol Phys. 2023; 115(3):746-758. doi: 10.1016/j.ijrobp.2022.08.047

[8] Bhandari A, Johnson K, Oh K, et al. Developing a novel dosiomics model to predict treatment failures following lung stereotactic body radiation therapy. Front Oncol. 2024;14:1438861. doi: 10.3389/fonc.2024.1438861